Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Surgical Science Sweden AB (publ) (SUS.ST)
Gothenburg, SE
Surgical Science Sweden AB (publ) specializes in the creation and distribution of virtual reality (VR) simulation platforms designed for evidence-backed training in laparoscopic and endoscopic procedures. Among its key offerings is the LapSim training system, which includes LapSim ST, tailored for educating surgical technologists and assistants, as well as LapSim essence, a compact and readily deployable VR simulator. The company's product portfolio further extends to the EndoSim system, a dedicated endoscopy simulator for comprehensive medical training. It also features TeamSim, an innovative platform fostering inter-professional education by integrating surgical simulation with real-world team dynamics. Additionally, they provide the Simball Box, which delivers velocity feedback alongside instructional task videos demonstrating optimal techniques, alongside their well-known Simbionix and robotic surgery simulators. Established in 1999, Surgical Science AB maintains its headquarters in Gothenburg, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.43% | +13.81% | +4.99% | +13.74% | -49.33% | +20.55% | -74.97% | -84.85% | -72.16% | +225.39% | +225.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%+12.3% Q1'26: -6.1% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%-49.2% Q1'26: -43.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+8.6% Q1'26: +20.1% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+11.0% ★ Q1'26: +9.7% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+2.0% Q1'26: +2.1% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×0.01× ★ Q1'26: 0.02× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 5 EPS Ana. |
Dec 2027 5 Rev. Ana. 5 EPS Ana. |
Dec 2028 5 Rev. Ana. 5 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
57.98M
est: 58.00M (0.0%)
|
65.70M
est: 76.61M (-14.2%)
|
101.52M
est: 116.39M (-12.8%)
|
104.80M
est: 107.55M (-2.6%)
|
366.78M
est: 328.54M (+11.6%)
|
802.54M
est: 783.86M (+2.4%)
|
882.85M
est: 838.25M (+5.3%)
|
884.09M
est: 892.51M (-0.9%)
|
992.34M
est: 996.06M (-0.4%)
|
995.98M
980.52M – 1.01B
0.0% YoY
|
1.12B
1.06B – 1.18B
+12.0% YoY
|
1.24B
1.23B – 1.25B
+11.2% YoY
|
1.46B
1.41B – 1.51B
+17.6% YoY
|
1.63B
1.58B – 1.69B
+12.0% YoY
|
| EBITDA |
-2.25M
est: 18.11M (-112.4%)
|
-1.95M
est: 23.92M (-108.2%)
|
30.37M
est: 36.34M (-16.5%)
|
30.22M
est: 33.59M (-10.0%)
|
115.05M
est: 102.60M (+12.1%)
|
271.30M
est: 244.78M (+10.8%)
|
324.53M
est: 245.91M (+32.0%)
|
224.29M
est: 261.83M (-14.3%)
|
192.34M
est: 292.21M (-34.2%)
|
292.18M
287.65M – 295.69M
0.0% YoY
|
327.16M
309.98M – 345.83M
+12.0% YoY
|
363.85M
360.18M – 367.51M
+11.2% YoY
|
427.87M
412.84M – 443.23M
+17.6% YoY
|
479.18M
462.35M – 496.38M
+12.0% YoY
|
| EBIT |
-4.19M
est: 13.99M (-129.9%)
|
-4.07M
est: 18.48M (-122.0%)
|
15.18M
est: 28.07M (-45.9%)
|
19.97M
est: 25.94M (-23.0%)
|
88.75M
est: 79.25M (+12.0%)
|
227.66M
est: 189.08M (+20.4%)
|
268.92M
est: 188.66M (+42.5%)
|
163.77M
est: 200.87M (-18.5%)
|
108.97M
est: 224.17M (-51.4%)
|
224.15M
220.68M – 226.84M
0.0% YoY
|
250.99M
237.81M – 265.31M
+12.0% YoY
|
279.13M
276.32M – 281.94M
+11.2% YoY
|
328.25M
316.72M – 340.03M
+17.6% YoY
|
367.61M
354.70M – 380.81M
+12.0% YoY
|
| Net Income |
-2.26M
est: -4.80M (+52.9%)
|
-4.52M
est: 4.19M (-207.8%)
|
12.60M
est: 30.64M (-58.9%)
|
15.61M
est: 30.94M (-49.6%)
|
86.25M
est: 57.27M (+50.6%)
|
187.97M
est: 112.10M (+67.7%)
|
233.97M
est: 197.72M (+18.3%)
|
131.65M
est: 150.18M (-12.3%)
|
66.82M
est: 86.56M (-22.8%)
|
102.50M
70.34M – 136.03M
+18.4% YoY
|
144.40M
109.99M – 171.91M
+40.9% YoY
|
186.94M
138.82M – 231.37M
+29.5% YoY
|
250.54M
239.10M – 262.23M
+34.0% YoY
|
296.97M
283.41M – 310.83M
+18.5% YoY
|
| SGA |
30.69M
est: 19.58M (+56.7%)
|
39.49M
est: 25.86M (+52.7%)
|
50.79M
est: 39.29M (+29.3%)
|
50.43M
est: 36.31M (+38.9%)
|
145.96M
est: 110.92M (+31.6%)
|
201.88M
est: 264.64M (-23.7%)
|
240.02M
est: 249.04M (-3.6%)
|
252.38M
est: 265.16M (-4.8%)
|
276.53M
est: 295.93M (-6.6%)
|
295.90M
291.31M – 299.45M
0.0% YoY
|
331.33M
313.92M – 350.24M
+12.0% YoY
|
368.48M
364.77M – 372.19M
+11.2% YoY
|
433.32M
418.10M – 448.87M
+17.6% YoY
|
485.28M
468.24M – 502.70M
+12.0% YoY
|
| EPS |
-0.12
est: -0.09 (-27.7%)
|
-0.19
est: 0.08 (-331.2%)
|
0.45
est: 0.60 (-25.1%)
|
0.45
est: 0.61 (-25.8%)
|
2.03
est: 1.12 (+80.9%)
|
3.70
est: 2.20 (+68.3%)
|
4.59
est: 3.87 (+18.5%)
|
2.58
est: 2.94 (-12.3%)
|
1.31
est: 1.70 (-22.9%)
|
2.05
1.38 – 2.67
+20.3% YoY
|
2.78
2.16 – 3.37
+35.7% YoY
|
3.47
2.72 – 4.53
+24.9% YoY
|
4.91
4.69 – 5.14
+41.7% YoY
|
5.82
5.55 – 6.09
+18.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-05 | A- | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 2/5 | 5/5 |
| 2026-05-04 | A- | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 | 2/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 2/5 | 5/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 2/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.01% | 112.6K | 0.40% |
| 2 | Avantis International Small Cap Equity ETF AVDS | 0.00% | 5.7K | 0.30% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Tom Englund | Chief Executive Officer | 4M | male |
| Anders Larsson | Co-Founder & Chief Technology Officer | — | male |
| Anna Ahlberg | Chief Financial Officer | — | female |
| Boaz Tal Adv. (CPA | Chief Operating Officer | — | male |
| Daniel Evestedt | Head of Development | — | male |
| Adele Horn | IR Manager | — | — |
| Inbal Mazor-Badichi | Chief Product & Marketing Officer | — | female |
| Jeffrey Berkley | Chief Innovation Officer | — | male |
| Martin Jansson | Head of Global Sales | — | male |
| Doron Zilberman | Executive Vice President of International Sales & Educational Products | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SUS.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
